HighTower Advisors LLC Purchases Shares of 12,456 Cellebrite DI Ltd. (NASDAQ:CLBT)

HighTower Advisors LLC acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,456 shares of the company’s stock, valued at approximately $274,000.

Several other institutional investors have also recently made changes to their positions in the business. Quarry LP purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $27,000. R Squared Ltd purchased a new position in shares of Cellebrite DI in the 4th quarter worth approximately $100,000. Victory Capital Management Inc. bought a new position in shares of Cellebrite DI during the 4th quarter valued at approximately $234,000. Steward Partners Investment Advisory LLC raised its holdings in Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after buying an additional 1,463 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its position in Cellebrite DI by 35.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,510 shares of the company’s stock worth $329,000 after buying an additional 5,113 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $19.83 on Thursday. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The stock has a market cap of $4.75 billion, a P/E ratio of -14.27, a P/E/G ratio of 4.27 and a beta of 1.52. The stock’s 50 day simple moving average is $20.62 and its 200-day simple moving average is $19.94.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CLBT shares. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a report on Wednesday. Finally, Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.